-
1
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
2
-
-
1542503746
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1
-
G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784
-
(2004)
J Clin Oncol
, vol.22
, pp. 777-784
-
-
Giaccone, G.1
Herbst, R.S.2
Manegold, C.3
-
3
-
-
77954700380
-
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
-
D.W. Miles, A. Chan, and L.Y. Dirix Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 3239 3247
-
(2010)
J Clin Oncol
, vol.28
, pp. 3239-3247
-
-
Miles, D.W.1
Chan, A.2
Dirix, L.Y.3
-
4
-
-
79953874259
-
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
-
N.J. Robert, V. Dieras, and J. Glaspy RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
-
(2011)
J Clin Oncol
, vol.29
, pp. 1252-1260
-
-
Robert, N.J.1
Dieras, V.2
Glaspy, J.3
-
5
-
-
77949503823
-
North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
-
E.A. Perez, D.W. Hillman, and T. Dentchev North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer Ann Oncol 21 2010 269 274
-
(2010)
Ann Oncol
, vol.21
, pp. 269-274
-
-
Perez, E.A.1
Hillman, D.W.2
Dentchev, T.3
-
6
-
-
53749093040
-
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
-
B.P. Schneider, M. Wang, and M. Radovich Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 2008 4672 4678
-
(2008)
J Clin Oncol
, vol.26
, pp. 4672-4678
-
-
Schneider, B.P.1
Wang, M.2
Radovich, M.3
-
7
-
-
77955019276
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial
-
A. Tutt, M. Robson, and J.E. Garber Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
-
(2010)
Lancet
, vol.376
, pp. 235-244
-
-
Tutt, A.1
Robson, M.2
Garber, J.E.3
-
8
-
-
79953879710
-
Biology-driven phase II trials: What is the optimal model for molecular selection?
-
F. Andre, S. Delaloge, and J.C. Soria Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 29 2011 1236 1238
-
(2011)
J Clin Oncol
, vol.29
, pp. 1236-1238
-
-
Andre, F.1
Delaloge, S.2
Soria, J.C.3
-
10
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
-
E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
11
-
-
0026072872
-
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
-
C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 1991 403 410
-
(1991)
Histopathology
, vol.19
, pp. 403-410
-
-
Elston, C.W.1
Ellis, I.O.2
-
12
-
-
33847147313
-
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
-
A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
-
(2007)
J Clin Oncol
, vol.25
, pp. 118-145
-
-
Wolff, A.C.1
Hammond, M.E.2
Schwartz, J.N.3
-
13
-
-
33645341566
-
Joint analysis of DNA copy numbers and gene expression levels
-
D. Lipson, A. Ben-Dor, and E.Z.Y. Dehan Joint analysis of DNA copy numbers and gene expression levels Algorithms Bioinform 3240 2004 135
-
(2004)
Algorithms Bioinform
, vol.3240
, pp. 135
-
-
Lipson, D.1
Ben-Dor, A.2
Dehan, E.Z.Y.3
-
14
-
-
0033756274
-
Comparative genomic hybridization of fine needle aspirates from breast carcinomas
-
N.G. Burki, R. Caduff, and H. Walt Comparative genomic hybridization of fine needle aspirates from breast carcinomas Int J Cancer 88 2000 607 613
-
(2000)
Int J Cancer
, vol.88
, pp. 607-613
-
-
Burki, N.G.1
Caduff, R.2
Walt, H.3
-
15
-
-
0035810148
-
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
-
H. Joensuu, P.J. Roberts, and M. Sarlomo-Rikala Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 2001 1052 1056
-
(2001)
N Engl J Med
, vol.344
, pp. 1052-1056
-
-
Joensuu, H.1
Roberts, P.J.2
Sarlomo-Rikala, M.3
-
16
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
17
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
C.E. Geyer, J. Forster, and D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743
-
(2006)
N Engl J Med
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
-
18
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
E.L. Kwak, Y.J. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
-
(2010)
N Engl J Med
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
-
19
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
20
-
-
59449094654
-
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
-
F. Andre, B. Job, and P. Dessen Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array Clin Cancer Res 15 2009 441 451
-
(2009)
Clin Cancer Res
, vol.15
, pp. 441-451
-
-
Andre, F.1
Job, B.2
Dessen, P.3
-
21
-
-
79957857433
-
The BATTLE Trial: Personalizing therapy for lung cancer
-
E.S. Kim, R.S. Herbst, and I. Wistuba The BATTLE Trial: personalizing therapy for lung cancer Cancer Discov 1 2011 44 53
-
(2011)
Cancer Discov
, vol.1
, pp. 44-53
-
-
Kim, E.S.1
Herbst, R.S.2
Wistuba, I.3
-
22
-
-
79951906119
-
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers
-
D.D. Von Hoff, J.J. Stephenson Jr., and P. Rosen Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers J Clin Oncol 28 2010 4877 4883
-
(2010)
J Clin Oncol
, vol.28
, pp. 4877-4883
-
-
Von Hoff, D.D.1
Stephenson, Jr.J.J.2
Rosen, P.3
-
23
-
-
0033031878
-
Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization
-
H. Bissig, J. Richter, and R. Desper Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization Am J Pathol 155 1999 267 274
-
(1999)
Am J Pathol
, vol.155
, pp. 267-274
-
-
Bissig, H.1
Richter, J.2
Desper, R.3
-
24
-
-
70349706155
-
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites
-
C. Gomez-Roca, C.M. Raynaud, and F. Penault-Llorca Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites J Thorac Oncol 4 2009 1212 1220
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1212-1220
-
-
Gomez-Roca, C.1
Raynaud, C.M.2
Penault-Llorca, F.3
|